Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation

被引:5
|
作者
Ning, Hui [1 ,2 ]
Liu, Ming [1 ]
Wang, Lina [3 ]
Yang, Yang [1 ]
Song, Nan [1 ]
Xu, Xiaoxiong [1 ]
Ju, Jin [4 ]
Jiang, Gening [1 ]
机构
[1] Tongji Univ, Dept Thorac Surg, Shanghai Pulm Hosp, 507 Zhengmin Rd, Shanghai 200433, Peoples R China
[2] Tianjin Haihe Hosp, Dept Thorac Surg, Tianjin 300350, Peoples R China
[3] Dalian Med Univ, Dept Endodont & Periodont, Coll Stomatol, Dalian 116044, Peoples R China
[4] Weihai Municipal Hosp, Dept Thorac Surg, 70 Heping Rd, Weihai 264200, Peoples R China
基金
中国博士后科学基金;
关键词
Lung cancer; epidermal growth factor receptor ( EGFR) gene; mutation; phenotype; genotype; EGFR MUTATIONS; TYROSINE KINASE; KRAS MUTATIONS; GEFITINIB; ADENOCARCINOMA; CHEMOTHERAPY; SENSITIVITY; INHIBITION; RESISTANCE; PATHWAYS;
D O I
10.21037/jtd.2017.03.13
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Epidermal growth factor receptor (EGFR) gene was the major causative gene of lung cancer and also the specific treatment target. It is necessary to analyze the genotype and phenotype characters of patients. Methods: We investigated 1,034 lung cancer patients in this study. The collected clinicopathological parameters included gender, age at diagnosis, smoking status, pathological TNM stage, tumor morphology and location, visceral pleural invasion as well as histological type. Results: Almost 50% participants had EGFR mutations. L858R in exon 21 was the most common type. Concomitant mutation, 19 del and L858R, were detected in 20 patients. Compared to patients with exon 19 del or L858R mutations solely, they were inclined to have small size adenocarcinomas which occurred in bilateral and invaded the visceral pleura. The tyrosine kinases inhibitors (TKIs)-resistant mutation, insertions in exon 20, was detected in 11 patients. Conclusions: The summarized clinicopathological features will help clinicians to implement the feasible treatment plan.
引用
下载
收藏
页码:796 / 801
页数:6
相关论文
共 50 条
  • [41] The biology of epidermal growth factor receptor in lung cancer
    Scagliotti, GV
    Selvaggi, G
    Novello, S
    Hirsch, FR
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4227S - 4232S
  • [42] Epidermal growth factor receptor mutations in lung cancer
    Sreenath V. Sharma
    Daphne W. Bell
    Jeffrey Settleman
    Daniel A. Haber
    Nature Reviews Cancer, 2007, 7 : 169 - 181
  • [43] Epidermal growth factor receptor mutations in lung cancer
    Sharma, Sreenath V.
    Bell, Daphne W.
    Settleman, Jeffrey
    Haber, Daniel A.
    NATURE REVIEWS CANCER, 2007, 7 (03) : 169 - 181
  • [44] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Sojung Park
    Sung Yong Lee
    Dojin Kim
    Yun Su Sim
    Jeong-Seon Ryu
    Juwhan Choi
    Su Hwan Lee
    Yon Ju Ryu
    Jin Hwa Lee
    Jung Hyun Chang
    BMC Cancer, 21
  • [45] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Park, Sojung
    Lee, Sung Yong
    Kim, Dojin
    Sim, Yun Su
    Ryu, Jeong-Seon
    Choi, Juwhan
    Lee, Su Hwan
    Ryu, Yon Ju
    Lee, Jin Hwa
    Chang, Jung Hyun
    BMC CANCER, 2021, 21 (01)
  • [46] Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma
    Hayasaka, Kazuki
    Shiono, Satoshi
    Matsumura, Yuki
    Yanagawa, Naoki
    Suzuki, Hiroyuki
    Abe, Jiro
    Sagawa, Motoyasu
    Sakurada, Akira
    Katahira, Masato
    Takahashi, Satomi
    Endoh, Makoto
    Okada, Yoshinori
    ANNALS OF THORACIC SURGERY, 2018, 105 (06): : 1648 - 1654
  • [47] Epidermal growth factor receptor mutations in Chinese patients with non-small cell lung cancer.
    Zhou, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 645S - 645S
  • [48] Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
    Wang, Changbin
    Zhang, Ran
    Sun, Xiaorong
    Xing, Ligang
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2024, 17 (02) : 100 - 106
  • [49] Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma
    Zhao, F. N.
    Zhao, Y. Q.
    Han, L. Z.
    Xie, Y. S.
    Liu, Y.
    Ye, Z. X.
    CLINICAL RADIOLOGY, 2019, 74 (01) : 80.e7 - 80.e17
  • [50] Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
    Roengvoraphoj, Monic
    Tsongalis, Gregory J.
    Dragnev, Konstantin H.
    Rigas, James R.
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 839 - 850